Harness, Dickey & Pierce, P.L.C.
Talen targeting blood coagulation factor VIII intron 1 inversion gene and composition for treating hemophilia comprising same
The present invention provides a method for inducing an inversion of normal blood coagulation factor VIII (F8) gene, a method for correcting an inversion of blood coagulation factor VIII gene in which the inversion has occurred, and a Hemophilia A patient-derived induced pluripotent stem cell in which the inversion is corrected, constructed using the same. The method of the present invention effectively reproduces the inversion of intron 1 and intron 22 of the F8 gene, which is responsible for the majority of severe hemophilia A, and thereby may be effectively used for studying the development mechanism of hemophilia A and as a research tool for screening therapeutic agents. The inversion-corrected induced pluripotent stem cell constructed according the method of the present invention enables an efficient and fundamental treatment for hemophilia A by restoring a genotype in which mutation has occurred to a wild type-like state, without limitation via normal gene or protein delivery.
INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
A C C C C A C C A C A C A A
A61K C12N C07K C12N C12N A61P C12N C12N A61K C12N A61K C12N A61P A61K
inventional additional inventional inventional inventional inventional inventional inventional inventional additional inventional additional inventional inventional
Jung Eun Duk Hyoung Chul Yong Dong Wook Jin Soo Jiyeon
Kim Kim Park Kim Kim Kweon